SCHEMBL4243701

SCHEMBL4243701

c1ccc2sc(-c3ncc[nH]3)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.46
MTOR P42345 1/20 0.46
ADK P55263 1/20 0.46
NISCH Q9Y2I1 1/20 0.46
CYP19A1 P11511 1/20 0.46
APP P05067 2/20 0.44
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
CCNT1 O60563 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CDK9 P50750 1/20 0.39
KDM1A O60341 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
NQO1 P15559 1/20 0.39
NQO2 P16083 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8787259 0.81 ALDH1A1 (0.46) ADRA2AMTORADKNISCHMEN1
SCHEMBL2581028 0.77 CYP19A1 (0.64) CYP19A1APPHSD17B1HSD17B2KDM1A
SCHEMBL845603 0.73 APP (0.63) CYP19A1APPHSD17B1HSD17B2CA1
SCHEMBL29732980 0.73 APP (0.63) CYP19A1APPHSD17B1HSD17B2CA1
SCHEMBL484134 0.72 NPC1 (0.58) MTORCDK2ALDH1A1
SCHEMBL17843576 0.72 APP (0.49) CYP19A1APPHSD17B1HSD17B2CA1
SCHEMBL29415478 0.70 CYP19A1 (0.60) CYP19A1APPKDM1ACYP11B1CYP11B2
SCHEMBL403651 0.70 CYP19A1 (0.60) CYP19A1APPKDM1ACYP11B1CYP11B2
SCHEMBL3850573 0.70 APP (0.44) CYP19A1APPHSD17B1HSD17B2KDM1A
SCHEMBL4791411 0.70 NPC1 (0.56) MTORADKNISCHCYP19A1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5602163-A SELECTIVE AGONISTS OF 5-HYDROXYTRYPTAMINE RECEPTORS; USEFUL IN TREATMENT OF MIGRAINE HEADACHES MERCK, SHARP & DOHME LTD. (GB) 1997-02-11 US claimed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 US disclosed
EP-1257551-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS PARP INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2002-11-20 EP disclosed
WO-2001057038-A9 HETEROCYCLIC COMPOUNDS AND THEIR USE AS PARP INHIBITORS BASF AG (DE) 2001-09-20 WO disclosed
WO-2001057038-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS PARP INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-08-09 WO disclosed
US-4447620-A SYNTHETASES INHIBITORS, ANTICOAGULANTS, ANTIINFLAMMATORY AND ANTIULCER AGENTS THE UPJOHN COMPANY (US) 1984-05-08 US disclosed
EP-0069521-A2 Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes THE UPJOHN COMPANY (US) 1983-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP ADRA2A 2546/4885MTOR 2473/4885ADK 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.